Filtros de búsqueda

Lista de obras de

Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection

artículo científico publicado en 2020

Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis

artículo científico publicado en 2019

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study

artículo científico publicado en 2021

HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study

artículo científico publicado en 2022

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study

artículo científico publicado en 2022

Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?

artículo científico publicado en 2018

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA

artículo científico publicado en 2020

Occurrence and clinical characteristics of hepatocellular carcinoma in the north-eastern Poland

artículo científico publicado en 2017

Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.

artículo científico publicado en 2019

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study

scholarly article by Ewa Janczewska et al published 16 November 2018 in BMC Infectious Diseases

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda